The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Beta Bionics Inc (NASDAQ: BBNX) was $17.65 for the day, down -12.36% from the previous closing price of $20.14. In other words, the price has decreased by -$12.36 from its previous closing price. On the day, 2.93 million shares were traded. BBNX stock price reached its highest trading level at $20.305 during the session, while it also had its lowest trading level at $17.42.
Ratios:
Our analysis of BBNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 10.64. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Goldman Upgraded its Neutral to Buy on October 01, 2025, while the target price for the stock was maintained at $26.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’26 when Mensinger Mike sold 2,200 shares for $30.10 per share. The transaction valued at 66,221 led to the insider holds 80,752 shares of the business.
Mensinger Mike sold 7,800 shares of BBNX for $230,950 on Jan 02 ’26. The Chief Product Officer now owns 82,952 shares after completing the transaction at $29.61 per share. On Jan 02 ’26, another insider, Feider Stephen, who serves as the Chief Financial Officer of the company, sold 20,000 shares for $29.53 each. As a result, the insider received 590,680 and left with 42,614 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 777034752 and an Enterprise Value of 556034752. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.77 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 6.278 whereas that against EBITDA is -8.259.
Stock Price History:
The Beta on a monthly basis for BBNX is 5.53, which has changed by -0.14769363 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, BBNX has reached a high of $32.71, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is -38.87%, while the 200-Day Moving Average is calculated to be -10.39%.
Shares Statistics:
BBNX traded an average of 897.81K shares per day over the past three months and 1419210 shares per day over the past ten days. A total of 43.99M shares are outstanding, with a floating share count of 33.43M. Insiders hold about 24.06% of the company’s shares, while institutions hold 95.27% stake in the company. Shares short for BBNX as of 1767139200 were 7301052 with a Short Ratio of 8.13, compared to 1764288000 on 3860691. Therefore, it implies a Short% of Shares Outstanding of 7301052 and a Short% of Float of 18.69.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.34 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.64 and -$2.06 for the fiscal current year, implying an average EPS of -$1.9. EPS for the following year is -$1.65, with 7.0 analysts recommending between -$1.27 and -$2.0.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $32M to a low estimate of $29M. As of. The current estimate, Beta Bionics Inc’s year-ago sales were $20.44MFor the next quarter, 7 analysts are estimating revenue of $27.51M. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $24.2M.
A total of 10 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $100.13M, while the lowest revenue estimate was $96.6M, resulting in an average revenue estimate of $97.83M. In the same quarter a year ago, actual revenue was $65.12MBased on 10 analysts’ estimates, the company’s revenue will be $132.63M in the next fiscal year. The high estimate is $143.98M and the low estimate is $123.81M.
